Pyxis Oncology(PYXS)
$1.68+0.27 (+19.15%)
PYXS
Pyxis Oncology financials statements
$1.68
At close:+0.27 (+19.15%)
Want to see PYXS full AI Analyst Report?
Pyxis Oncology (PYXS) Ratios
704 Followers
Pyxis Oncology Ratios
PYXS's free cash flow for Q3 2026 was $-16.29M. For the 2026 fiscal year, PYXS's free cash flow was increased by $0.00 and operating cash flow was $-16.29M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 |
| Quick Ratio | 3.41 | 7.49 | 4.84 | 5.90 | 14.90 |
| Cash Ratio | 0.73 | 1.10 | 0.38 | 5.67 | 14.69 |
| Solvency Ratio | -1.97 | -2.04 | -1.50 | -2.37 | -4.03 |
| Operating Cash Flow Ratio | -3.01 | -3.26 | -2.75 | -2.82 | -1.89 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 33.99M | $ 96.01M | $ 76.58M | $ 136.06M | $ 259.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.20 | 0.13 | 0.12 | 0.09 | 0.00 |
| Debt-to-Equity Ratio | 0.35 | 0.17 | 0.17 | 0.12 | 0.00 |
| Debt-to-Capital Ratio | 0.26 | 0.14 | 0.15 | 0.11 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.71 | 1.30 | 1.38 | 1.31 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.30 | 0.35 | 0.53 | 0.57 | 0.01 |
| Net Debt to EBITDA | -0.04 | -0.01 | -0.15 | 1.31 | 3.98 |
| Profitability Margins | |||||
| Gross Profit Margin | 82.77% | 97.06% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -564.55% | -424.23% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -532.00% | -405.76% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -609.18% | -554.07% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -564.55% | -492.35% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -574.55% | -478.95% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -574.55% | -478.95% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 101.77% | 97.28% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.67% | 88.86% | 89.77% | 97.76% | 108.98% |
| Return on Assets (ROA) | -87.00% | -49.20% | -42.47% | -57.11% | -27.13% |
| Return on Equity (ROE) | -149.08% | -64.04% | -58.70% | -75.06% | -29.07% |
| Return on Capital Employed (ROCE) | -119.93% | -64.13% | -55.55% | -68.70% | -26.68% |
| Return on Invested Capital (ROIC) | -117.12% | -61.74% | -55.09% | -68.70% | -26.66% |
| Return on Tangible Assets | -87.00% | -50.03% | -49.38% | -57.11% | -27.13% |
| Earnings Yield | -111.41% | -84.82% | -102.73% | -272.72% | -21.49% |
| Efficiency Ratios | |||||
| Receivables Turnover | 19.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.22 | 0.10 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.71 | 0.73 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.15 | 0.10 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.17 | 0.15 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1645.31 | -3733.76 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 18.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1663.75 | 3733.76 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 18.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.02 | -0.99 | -1.77 | -2.70 | -1.10 |
| Free Cash Flow Per Share | -1.02 | -0.99 | -1.94 | -2.90 | -1.11 |
| Dividend Paid and CapEx Coverage Ratio | -7055.78 | -243.34 | -10.51 | -13.96 | -65.42 |
| Capital Expenditure Coverage Ratio | -7055.78 | -243.34 | -10.51 | -13.96 | -65.42 |
| Operating Cash Flow Coverage Ratio | -3.40 | -2.86 | -3.31 | -4.72 | -214.10 |
| Operating Cash Flow to Sales Ratio | -4.58 | -3.57 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -88.87% | -63.51% | -107.81% | -216.28% | -10.15% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.90 | -1.18 | -0.97 | -0.37 | -4.65 |
| Price-to-Sales (P/S) Ratio | 5.16 | 5.65 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.34 | 0.76 | 0.57 | 0.28 | 1.35 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.13 | -1.57 | -0.93 | -0.46 | -9.86 |
| Price-to-Operating Cash Flow Ratio | -1.13 | -1.58 | -1.02 | -0.50 | -10.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.30 | 0.04 | 0.02 | -0.01 | -0.01 |
| Enterprise Value Multiple | -1.01 | -1.40 | -1.04 | 0.95 | -1.14 |
| Enterprise Value | 74.72M | 91.90M | 83.50M | -116.11M | 78.92M |
| EV to EBITDA | -1.01 | -1.40 | -1.04 | 0.95 | -1.14 |
| EV to Sales | 5.39 | 5.69 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.18 | -1.59 | -1.08 | 1.21 | -2.20 |
| EV to Operating Cash Flow | -1.18 | -1.59 | -1.18 | 1.30 | -2.23 |
| Tangible Book Value Per Share | 0.86 | 2.02 | 2.54 | 4.87 | 8.11 |
| Shareholders’ Equity Per Share | 0.86 | 2.07 | 3.15 | 4.87 | 8.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.03 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.22 | 0.28 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.28 | -1.32 | -1.85 | -3.65 | -2.36 |
| Tax Burden | 1.02 | 0.97 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.16 | 0.90 | 0.98 | 1.09 |
| Research & Development to Revenue | 5.32 | 3.64 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.60 | 1.57 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.85 | 0.80 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.80 | 0.75 | 0.96 | 0.74 | 0.46 |
Currency in USD

